Detalhe da pesquisa
1.
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
N Engl J Med
; 388(8): 719-732, 2023 02 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-36795891
2.
Rociletinib in EGFR-mutated non-small-cell lung cancer.
N Engl J Med
; 372(18): 1700-9, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25923550
3.
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
Eur Urol
; 83(3): 200-209, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36243543
4.
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Eur Urol
; 84(3): 321-330, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277275
5.
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study.
JTO Clin Res Rep
; 2(2): 100114, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34589984
6.
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.
Clin Cancer Res
; 27(24): 6677-6686, 2021 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34598946
7.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
J Clin Oncol
; 38(32): 3763-3772, 2020 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32795228
8.
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Clin Cancer Res
; 26(11): 2487-2496, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32086346
9.
Natalizumab induction and maintenance therapy for Crohn's disease.
N Engl J Med
; 353(18): 1912-25, 2005 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-16267322
10.
Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
Clin Lung Cancer
; 19(6): 518-530.e7, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30279111
11.
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
JCO Precis Oncol
; 2: 1-13, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-35135111
12.
Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686).
Clin Cancer Res
; 22(10): 2386-95, 2016 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26747242
13.
Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.
Chest
; 143(2): 315-323, 2013 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22814814
14.
ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension.
Cardiovasc Ther
; 30(2): 93-9, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21884013
15.
Long-term pulmonary hemodynamic effects of ambrisentan in pulmonary arterial hypertension.
Am J Cardiol
; 108(2): 302-7, 2011 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21545989
16.
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
Chest
; 135(1): 122-129, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18812445
17.
Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension.
J Am Coll Cardiol
; 54(21): 1971-81, 2009 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-19909879